Mr. Shaun Flanagan:

We are responsible for reimbursement. The EMA does not look at that issue. It looks at quality, safety and efficacy. It does not have to look at value for money. We are responsible for medicines that have EMA authorisations and consider the costs in the context of the Health Act, which requires us to look at cost effectiveness, value for money and the resources available to us.